William Ondo, MD

home / authors / william-ondo-md

Director, Movements Disorders Clinic, Houston Methodist Neurological Institute; and professor of neurology, Weill Cornell Medical College

Articles

Unmet Needs and Improving Diagnosis of Dyskinesia in Parkinson Disease

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

May 9th 2023

The expert panel reviews unmet needs in treatment and management of dyskinesia and shares advice for physicians treating patients with Parkinson disease.

Surgical Options and Emerging Treatments for Parkinson Disease

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

May 9th 2023

Drs Fernando Pagan, Robert A. Hauser, and Daniel Kremens highlight existing and emerging surgical and pharmacological options for treatment of dyskinesia in Parkinson disease.

Use of Other Amantadine Formulations in Parkinson Disease

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

May 2nd 2023

The expert neurology panel shares their clinical experience with different formulations of amantadine in management of dyskinesia in patients with Parkinson disease.

Amantadine DR/ER for Dyskinesia in Parkinson Disease: Safety Profile and Ideal Patient

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

May 2nd 2023

The expert panel reviews the safety profile of amantadine DR/ER and who may be an ideal patient for its use in patients with Parkinson disease experiencing dyskinesia.

Studies With Amantadine-DR/ER for Treatment of Dyskinesia

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

April 25th 2023

The expert neurology panel discusses clinical trial data of amantadine-DR/ER in treatment of dyskinesia and OFF episodes in Parkinson disease.

Amantadine Formulations in Treatment of Dyskinesia in Parkinson Disease

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

April 25th 2023

Drs William G. Ondo and Rajesh Pahwa analyze the pharmacokinetics of different formulations of amantadine for treatment of dyskinesia in Parkinson disease.

Treatment of Dyskinesia in Patients with Parkinson’s Disease

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

April 18th 2023

Drs Rajesh Pahwa, Daniels Kremens and Fernando Pagan provide an overview of current treatment options for treatment of dyskinesia in patients with Parkinson’s Disease.

Challenges in Balancing Treatment of OFF Episodes and Dyskinesia in Parkinson Disease

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

April 18th 2023

The expert panel highlights challenges in treatment of OFF episodes and dyskinesia together and long-term consequences of delaying treatment for dyskinesia in patients with Parkinson disease.

Diagnosis of Dyskinesia and Impact on Quality of Life of Patients With Parkinson Disease

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

April 11th 2023

The expert panel shares strategies for accurate clinical diagnosis of dyskinesia in patients with Parkinson disease and discusses how dyskinesia may impact the quality of life.

Risk Factors for Dyskinesia in Patients With Parkinson Disease

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

April 11th 2023

The expert neurology panel examines risk factors for development of dyskinesia in patients with Parkinson disease.

Pathophysiology of Dyskinesia in Parkinson Disease

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

April 4th 2023

Drs William G. Ondo and Robert A. Hauser discuss the understanding of pathophysiology and clinical features of dyskinesia in patients with Parkinson disease.

Challenges With Parkinson Disease Treatments

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

April 4th 2023

Drs Rajesh Pahwa and Daniel E. Kremens discuss challenges with Parkinson disease treatment and management of motor fluctuations, dyskinesia and OFF episodes in patients.

Use of Parkinson Disease Treatments and Identification of OFF Episodes in Clinical Practice

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

March 28th 2023

The expert panel discusses advances in formulations of carbidopa/levodopa and identification of OFF and ON time in patients with Parkinson disease.

Treatment Options for Parkinson Disease

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

March 28th 2023

Dr William G. Ondo provides an overview of available treatments and pharmacokinetic properties of different drugs for Parkinson Disease.

Parkinson’s Disease: Advice for Community Neurologists

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

November 23rd 2021

Expert neurologists provide insight on how to decide on an on-demand therapy for Parkinson’s disease and provide some general advice.

Sublingual Apomorphine for Parkinson’s Disease

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

November 23rd 2021

Key opinion leaders explain the use of sublingual apomorphine and trimethobenzamide for Parkinson’s disease.

Side Effects of Apomorphine Usage in Parkinson’s Disease

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

November 16th 2021

A panel of experts debate the disadvantages and side effects of apomorphine therapies for Parkinson’s disease.

Apomorphine Subcutaneous Injections for Parkinson’s Disease

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

November 16th 2021

A discussion on the use of apomorphine subcutaneous injections in managing Parkinson’s disease.

Levodopa Inhalation Powder for Parkinson’s Disease

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

November 9th 2021

Neurologists debate the use of levodopa inhalation powder in managing Parkinson’s disease.

When to Use On-Demand Therapies in Parkinson’s Disease

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

November 9th 2021

Physicians discuss when to add on-demand therapies to Parkinson’s disease management.

Important Attributes of On-Demand Therapies for Parkinson’s Disease

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

November 2nd 2021

Key opinion leaders explain the important attributes to consider when choosing an on-demand therapy.

The Relationship Between the Gut and Parkinson’s Disease

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

November 2nd 2021

Experts debate the challenges of carbidopa/levodopa, and the relation between levodopa and the gut.

Motor and Non-Motor Symptoms in Parkinson’s Disease

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

October 26th 2021

Panelists describe the motor and non-motor symptoms of Parkinson’s disease, linking symptoms to OFF episodes, and how to educate patients.

Parkinson’s Disease: Evaluating Patients for OFF Episodes

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

October 26th 2021

A discussion on how patients are evaluated for OFF episodes, by expert neurologists.

Expected and Unexpected OFF Episodes in Parkinson’s Disease

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

October 19th 2021

Physicians explain expected versus unexpected OFF episodes and the use of symptom diaries in managing Parkinson’s disease.

Impact of Parkinson’s Disease OFF Episodes on Quality of Life

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

October 19th 2021

Key opinion leaders provide insight on how OFF episodes affect patients’ quality of life.

Parkinson’s Disease: Why do OFF Episodes Occur?

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

October 12th 2021

Expert neurologists discuss why OFF episodes happen and how soon they occur after starting levodopa.

OFF Episodes in Parkinson’s Disease

Stuart H. Isaacson, MD, FAAN;Laxman Bahroo, DO;Khashayar Dashtipour, MD;Daniel E. Kremens, MD, JD;William Ondo, MD

October 12th 2021

Panelists have a conversation on the definition of OFF episodes in relation to Parkinson’s disease and how common OFF episodes are for patients.

State of Care for Patients With Parkinson Disease: William Ondo, MD

William Ondo, MD

September 19th 2021

The professor of neurology at Weill Cornell Medical School commented on the available treatments for Parkinson disease, as well as ongoing therapeutic development.

Efficacy, Safety, and Tolerability of Apomorphine Sublingual Film: William Ondo, MD

William Ondo, MD

September 17th 2021

The director of the Movements Disorders Clinic at Houston Methodist Neurological Institute discussed data presented at the International Parkinson and Movement Disorders Society Virtual Congress 2021.